Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 5/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.33 |
| ▸ | ITGAL | P20701 | 5/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955234 | 1.00 | ITGB2 (0.33) | ITGB2ICAM1ITGALUSP2MAPK1 | |
| SCHEMBL29736284 | 0.93 | NLRP3 (0.33) | — | |
| SCHEMBL21954952 | 0.91 | ITGB2 (0.34) | ITGB2ICAM1ITGALUSP2MAPK1 | |
| SCHEMBL21954953 | 0.91 | ITGB2 (0.34) | ITGB2ICAM1ITGALUSP2MAPK1 | |
| SCHEMBL21954960 | 0.87 | ITGB2 (0.36) | ITGB2ICAM1ITGALUSP2MAPK1 | |
| SCHEMBL21954961 | 0.87 | ITGB2 (0.36) | ITGB2ICAM1ITGALUSP2MAPK1 | |
| SCHEMBL21954959 | 0.87 | ITGB2 (0.36) | ITGB2ICAM1ITGALUSP2MAPK1 | |
| SCHEMBL21955173 | 0.86 | USP2 (0.30) | USP2MAPK1 | |
| SCHEMBL21955171 | 0.86 | USP2 (0.30) | USP2MAPK1 | |
| SCHEMBL21955055 | 0.85 | ITGB2 (0.35) | ITGB2ICAM1ITGALUSP2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| CN-112996786-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGB2 5/4885ICAM1 32/4885ITGAL 6/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGB2 5/4885ICAM1 32/4885ITGAL 6/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | ITGB2 5/4885ICAM1 32/4885ITGAL 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.